Fellow of the Academy of Medical Sciences

Sparrow Pharmaceuticals to Present on HSD-1 Inhibitor SPI-62 at Endocrine Society 2023 Annual Conference

Retrieved on: 
Thursday, June 8, 2023
Health, Other Health, General Health, Research, Science, Pharmaceutical, Biotechnology, ENDO, Prednisolone, Endocrinology, FRCP, University, Polymyalgia rheumatica, Sparrow, University of Leeds, Cortisol, Saint Andrew's Society, Brain, Doctor of Philosophy, Medication, MD, Rheumatology, Endocrine Society, Disease, Conference, Pharmaceutical industry, Fellow of the Academy of Medical Sciences

Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, will present the rationale that its lead candidate and HSD-1 inhibitor, SPI-62, is predicted to be associated with limited adrenal insufficiency risk in Cushing’s syndrome during a poster session at the Endocrine Society (ENDO) 2023 Annual Conference .

Key Points: 
  • Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, will present the rationale that its lead candidate and HSD-1 inhibitor, SPI-62, is predicted to be associated with limited adrenal insufficiency risk in Cushing’s syndrome during a poster session at the Endocrine Society (ENDO) 2023 Annual Conference .
  • The meeting will be held in-person from June 15-18, 2023 in Chicago, IL.
  • Presentation title: Intracellular Cortisol Control: An Approach to Reduce Cushing’s Syndrome Morbidity With Minimal Adrenal Insufficiency Risk?
  • To learn more about Sparrow Pharmaceuticals SPI-62, visit www.sparrowpharma.com .

Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference

Retrieved on: 
Monday, June 5, 2023
Candel, Webcast, Therapy, CADL, MD, Patient, Conference, News, Doctor of Philosophy, Pharmaceutical industry, Broadcasting, Fellow of the Academy of Medical Sciences

NEEDHAM, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will give a corporate presentation at the upcoming Jefferies Healthcare Conference, taking place June 7 – 9, 2023, in New York City.

Key Points: 
  • NEEDHAM, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will give a corporate presentation at the upcoming Jefferies Healthcare Conference, taking place June 7 – 9, 2023, in New York City.
  • A live webcast of the session will be available by selecting Events and Presentations under the News & Events tab in the Investors section on Candel.com .
  • A replay of the webcast will be archived for up to 90 days following the session date.

Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

Retrieved on: 
Friday, May 19, 2023
HSV, Survival rate, Injection, Arm, Histology, Gene, Neoplasm, Survival, Clinical trial, Cyclophosphamide, Nestin, SOC, Doctor of Philosophy, HIV disease progression rates, MD, Patient, Standard of care, Cell, MOS, Therapy, CADL, Society, Safety, Pharmaceutical industry, Vaccine, Candel, Fellow of the Academy of Medical Sciences

The data were presented today in an Oral Presentation Session at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT).

Key Points: 
  • The data were presented today in an Oral Presentation Session at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT).
  • “We are encouraged by the increased survival of treated patients in two independent cohorts observed to date.
  • mOS in arm B is ongoing at 12.0 months and supports the encouraging clinical activity of CAN-3110 observed in in arm A.
  • Additional extensive biomarker studies including histology, transcriptomics, and single cell sequencing are ongoing.

Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, May 11, 2023
Pancreatic cancer, Injection, University, Gene, Quarter, Survival, Clinical trial, Quality of life, Lung cancer, University of Pennsylvania, NSCLC, SOC, Perelman School of Medicine at the University of Pennsylvania, Doctor of Philosophy, Associate, ASCO, Development, American Society of Clinical Oncology, Patient, Standard of care, Administration, HGG, Annual general meeting, Cell, American Society of Gene and Cell Therapy, Cancer, PD-1, Research, FDA, Therapy, CADL, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MPH, Valaciclovir, Society, MOS, Food, Prostate cancer, Pharmaceutical industry, Q3, Candel, Fellow of the Academy of Medical Sciences, MD

NEEDHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.

Key Points: 
  • NEEDHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.
  • Financial Results for the Quarter Ended March 31, 2023
    Research and Development Service Revenue, related party: Research and development service revenue, related party, was $0 for the first quarter of 2023 compared to $31,000 for the first quarter of 2022.
  • Research and Development Expenses: Research and development expenses were $5.5 million for the first quarter of 2023 compared to $5.4 million for the first quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $4.2 million for the first quarter of 2023 compared to $3.6 million for the first quarter of 2022.

Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer

Retrieved on: 
Monday, April 17, 2023
Survival, Clinical trial, Lung cancer, NSCLC, Doctor of Philosophy, HIV disease progression rates, MD, Patient, Neoplasm, PD-1, FDA, Pembrolizumab, CADL, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Valaciclovir, Food, Pharmaceutical industry, Candel, Fellow of the Academy of Medical Sciences

Fast track designation is a process designed to facilitate the development and expedite the review of medicines to treat serious conditions and fulfill an unmet medical need.

Key Points: 
  • Fast track designation is a process designed to facilitate the development and expedite the review of medicines to treat serious conditions and fulfill an unmet medical need.
  • An investigational medicine that receives fast track designation may be eligible for more frequent interactions with the FDA to discuss the candidate’s development plan and, if relevant criteria are met, eligibility for accelerated approval and priority review.
  • “We are pleased with the FDA's decision to grant fast track designation for CAN-2409, which reinforces our belief that our investigational medicine has meaningful potential to treat those living with late-stage lung cancer,” said Paul Peter Tak, MD, PhD, FMedSci, President and CEO of Candel.
  • “Despite progress made in recent years, there remains a significant unmet need for patients with lung cancer who have an inadequate response to standard of care immune checkpoint inhibitors.

MITCHELL KENNEDY TO LEAD THE JACKSON LABORATORY'S JAX® MICE, CLINICAL AND RESEARCH SERVICES BUSINESS

Retrieved on: 
Tuesday, April 4, 2023
Zoology, Mouse, Drug development, CMD, Applied Biosystems, Therapy, Genetic engineering, University, Berkeley, Marketing, Marine biology, Cancer, Chromatography, Oregon Institute of Marine Biology, Research, Thermo Fisher Scientific, Mass spectrometry, Oregon Institute, Jackson Laboratory, IVF, Cryopreservation, Organization, Bio-Rad Laboratories, University of Oregon, Fellow of the Academy of Medical Sciences, JAX, PerkinElmer, Mitchell, BAR, Affymetrix, Management

Approximately 2,400 organizations in 68 countries rely on over 13,000 strains of genetically-specialized JAX® Mice and research services in a wide range of therapeutic areas.

Key Points: 
  • Approximately 2,400 organizations in 68 countries rely on over 13,000 strains of genetically-specialized JAX® Mice and research services in a wide range of therapeutic areas.
  • In addition, JAX provides a variety of services to the research community including preclinical in-vivo pharmacology services, mouse model generation (e.g., genetic engineering), custom breeding services, assisted reproductive technologies (e.g., cryopreservation and IVF services), and cancer genomic testing services.
  • In this position, Kennedy will drive product development, business development, business unit management, marketing, field representation, and customer support for JMCRS, as well as lead all JMCRS operational groups.
  • "The Jackson Laboratory's scientific and academic reputation precedes itself, and I have admired the organization throughout my entire career," said Kennedy.

Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 30, 2023
HSV, Pancreatic cancer, Insurance, Herpes simplex virus, University, Partnership, ICI, Survival, Clinical trial, Silicon Valley Bank, Immunotherapy, Nestin, Toxicity, Brain, NSCLC, Lung cancer, Doctor of Philosophy, TWELVE, Rated R, MS, University of Pennsylvania, Silicon, Development, HIV disease progression rates, Patient, Standard of care, Content discovery platform, Administration, HGG, Biology, PD-1, Research, Therapy, CADL, Tumor microenvironment, PD-L1, Valaciclovir, Nivolumab, Prostate cancer, Enlightenment, Pharmaceutical industry, Vaccine, Medical imaging, Cryptocurrency, Society, Candel, SOC, Cancer, Fellow of the Academy of Medical Sciences, MD

In addition, a single injection of CAN-3110 in patients with recurrent high-grade glioma resulted in a median overall survival of 11.6 months.

Key Points: 
  • In addition, a single injection of CAN-3110 in patients with recurrent high-grade glioma resulted in a median overall survival of 11.6 months.
  • Importantly, CAN-2409 demonstrated a favorable change in the trajectory of tumor growth in all patients for whom pre-enrollment scans were available.
  • The Company is encouraged by the results and plans to present additional data in Q3 2023.
  • Research and Development Expenses: Research and development expenses were $5.0 million for the fourth quarter of 2022 compared to $3.9 million for the fourth quarter of 2021, and $20.8 million for the full-year 2022 compared to $15.2 million for the full-year 2021.

Citryll Announces the Appointment of Paul Peter Tak as Chair of the Board of Directors

Retrieved on: 
Thursday, March 30, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, GSK, GSK plc, University, Netherlands Society for Statistics and Operations Research, Therapy, Senior, Arthritis, Medicine, European Alliance of Associations for Rheumatology, Infection, Cancer, University of California, San Diego, Fellow of the Academy of Medical Sciences, ViiV Healthcare, Doctor of Philosophy, Pain, Professor, Patient, Hidradenitis suppurativa, Medal, Immune-mediated inflammatory diseases, EULAR, Victoria Medal of Honour, Leiden University Medical Center, European Alliance, Rheumatoid arthritis, Pharmaceutical industry, Candel, Rheumatology, Citryl-CoA lyase

Citryll , a clinical-stage biotech company developing first-in-class therapeutics to treat autoimmune and autoinflammatory diseases, today announced that Dr. Paul Peter Tak, Citryll Board member since 2021, has been appointed Chair of the Board of Directors.

Key Points: 
  • Citryll , a clinical-stage biotech company developing first-in-class therapeutics to treat autoimmune and autoinflammatory diseases, today announced that Dr. Paul Peter Tak, Citryll Board member since 2021, has been appointed Chair of the Board of Directors.
  • At GlaxoSmithKline (GSK) Paul Peter served as Senior Vice President, Chief Immunology Officer and Global Development Leader.
  • He was the Chair of GSK’s Scientific Review Board, the governing body accountable for the scientific assessment of its R&D portfolio.
  • “We are delighted to welcome Paul Peter as Chair of the Board of Directors.

The Jackson Laboratory appoints Gina Rodriguez as its new vice president of advancement

Retrieved on: 
Tuesday, February 14, 2023
Jackson Laboratory, Organization, The arts, Children's Hospital, JAX, Fellow of the Academy of Medical Sciences, Data science, Hospital, Anne, Francis W. Parker School (Chicago), University, Health, Research, Francis, Laboratory, Museum, Shedd Aquarium, Growth, University of California, San Diego, BAR, Bachelor of Arts, Management

BAR HARBOR, Maine, Feb. 14, 2023 /PRNewswire/ -- The Jackson Laboratory (JAX) has appointed Gina Rodriguez as vice president of advancement.

Key Points: 
  • BAR HARBOR, Maine, Feb. 14, 2023 /PRNewswire/ -- The Jackson Laboratory (JAX) has appointed Gina Rodriguez as vice president of advancement.
  • Rodriguez will lead the Laboratory's advancement team and be responsible for philanthropic efforts in support of JAX's mission to improve human health.
  • "I'm so pleased to join The Jackson Laboratory and its talented and dedicated team," said Rodriguez.
  • Rodriguez graduated from the University of California, San Diego with a Bachelor of Arts in French literature and minor in computer science.

Paul Flicek, D.Sc. joins JAX as inaugural chief data science officer to build global data science initiative

Retrieved on: 
Wednesday, February 8, 2023
Jackson Laboratory, EMBL, Master of Science, Fellow of the Academy of Medical Sciences, JAX, Drake University, Data science, ENCODE, EMBL-EBI, Biomedical engineering, Computational biology, University, Research, Reference genome, Genetics, European Molecular Biology Laboratory, Laboratory, Physics, International, International Human Epigenome Consortium, Partnership, BAR, Genomics, Faculty, European Bioinformatics Institute, European, Ensembl genome database project, Washington University in St. Louis, Management, Science

BAR HARBOR, Maine, Feb. 8, 2023 /PRNewswire/ -- The Jackson Laboratory (JAX) has appointed world-class data scientist Paul Flicek, D.Sc., as its inaugural chief data science officer (CDSO).

Key Points: 
  • BAR HARBOR, Maine, Feb. 8, 2023 /PRNewswire/ -- The Jackson Laboratory (JAX) has appointed world-class data scientist Paul Flicek, D.Sc., as its inaugural chief data science officer (CDSO).
  • In this new leadership role, Flicek will be responsible for building and executing a comprehensive data science strategy across JAX.
  • "Dr. Flicek's contributions to open genomic resources have had a substantial impact on the global scientific community," said JAX President and CEO Lon Cardon , Ph.D., FMedSci.
  • Flicek will create new data science capabilities for JAX by envisioning and executing strategies to enhance the research and discovery enterprise and building a robust team of data scientists.